Allogenetics
PrivateLast Round
Early Funding
Sep 9, 2026
Total Funding Raised
$8.18M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Allogenetics operates in Healthcare & Life Sciences and is based in Germany. Its latest recorded funding round was an Early Funding round in September 2026.
Allogenetics is a biotechnology company developing a therapeutic approach that treats a donor organ to prevent rejection by the recipient's immune system.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Allogenetics Comparables
Compare Allogenetics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Medeor Therapeutics | 76% | |
| Quell Therapeutics | 70% | |
| eGenesis | 65% |
For institutional investors. Book with your work email.
Allogenetics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Sep 9, 2026 | ||||
| Seed | Sep 4, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Allogenetics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ascenion | Seed |
| NBank Capital | Early Funding, Seed |
| CARMA FUND | Early Funding, Seed |
| Life Science Valley Wachstumsfonds | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 9, 2026
$4.4M raised, led by NBank Capital.
- Aug 21, 2026
Grew 19% QoQ, from 16 to 19 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 1, 2026
Allogenetics GmbH appointed Dr. Olaf Schermeier as Chairman of its Advisory Board in Germany on Oct 1st '26.
For institutional investors. Book with your work email.
Allogenetics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Allogenetics's valuation, stock price, and market status.
Is Allogenetics a public or private company?
Allogenetics is a private company.
What is the current stock price of Allogenetics?
Allogenetics is a private company, so its shares have no public market price. Caplight tracks Allogenetics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Allogenetics worth (valuation)?
Valuation information for Allogenetics is not publicly available.
Can I buy Allogenetics stock?
Allogenetics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Allogenetics's last funding round?
Allogenetics's most recent funding round was Early Funding on September 9, 2026.
Who are the main investors in Allogenetics?
Key investors in Allogenetics include NBank Capital, CARMA FUND.
Will Allogenetics IPO soon?
No public IPO plans have been announced for Allogenetics.
How can I track Allogenetics secondary market activity?
Caplight tracks bids, offers, and trades in Allogenetics's shares on secondary markets.